{"id":7140,"date":"2025-04-29T14:03:05","date_gmt":"2025-04-29T14:03:05","guid":{"rendered":"https:\/\/stoxpo.com\/?p=7140"},"modified":"2025-04-29T14:03:07","modified_gmt":"2025-04-29T14:03:07","slug":"novo-nordisk-expands-wegovy-access-through-telehealth-providers","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/04\/29\/novo-nordisk-expands-wegovy-access-through-telehealth-providers\/","title":{"rendered":"Novo Nordisk Expands Wegovy Access Through Telehealth Providers"},"content":{"rendered":"\n

Partnership with Hims & Hers, Ro, and LifeMD aims to capture patients as compounded versions disappear<\/h4>\n\n\n\n

Novo Nordisk (NVO) is expanding access to its blockbuster weight loss drug Wegovy by partnering with telehealth companies Hims & Hers Health (HIMS), Ro, and LifeMD. The Danish pharmaceutical giant made the announcement Tuesday, signaling a strategic move to capture a broader share of the U.S. obesity treatment market now that Wegovy is no longer in short supply.<\/p>\n\n\n\n

The move comes as legally restricted compounding pharmacies phase out cheaper, unapproved versions of semaglutide\u2014the active ingredient in Wegovy. \u201cWe\u2019re really pleased about the level of interest to access branded Wegovy and to start to catch people as they come off of compounded medicine,\u201d said Dave Moore, executive vice president of U.S. operations at Novo Nordisk.<\/p>\n\n\n\n

Shares of Hims & Hers soared 30% in premarket trading following the announcement, while Novo Nordisk rose 3%.<\/p>\n\n\n\n

Patients will be able to access Wegovy directly through Novo Nordisk\u2019s new online pharmacy, NovoCare, integrated with the three telehealth platforms. Ro announced it would offer all doses of Wegovy for $499 per month, alongside 24\/7 messaging and coaching through its Body Program. Hims & Hers customers will pay more, reflecting the bundled access to care, according to CEO Andrew Dudum.<\/p>\n\n\n\n

This partnership marks a significant shift from earlier months when compounded semaglutide dominated due to Wegovy\u2019s limited supply. Now, with compounding restrictions tightening\u2014especially with federal deadlines on bulk manufacturing taking effect by May 22\u2014Novo Nordisk is seizing the opportunity to solidify its market position with FDA-approved products.<\/p>\n\n\n\n

\u201cThe spirit of this is that we stay true to what the rules are,\u201d Moore emphasized. \u201cThat\u2019s the best way for us to serve patients.\u201d<\/p>\n\n\n\n

With major telehealth providers on board, Novo Nordisk is poised to expand its reach among patients seeking clinically approved weight loss solutions.<\/p>\n\n\n\n

You might like this article:Boeing Shares Climb After Analyst Upgrade and Spirit AeroSystems Breakthrough<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Partnership with Hims & Hers, Ro, and LifeMD aims to capture patients as compounded versions disappear Novo Nordisk (NVO) is expanding access to its blockbuster weight loss drug Wegovy by partnering with telehealth companies Hims & Hers Health (HIMS), Ro, and LifeMD. The Danish pharmaceutical giant made the announcement Tuesday, signaling a strategic move to […]<\/p>\n","protected":false},"author":2,"featured_media":1139,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[308,361],"tags":[421,416,418,493,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7140"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=7140"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7140\/revisions"}],"predecessor-version":[{"id":7141,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7140\/revisions\/7141"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1139"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=7140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=7140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=7140"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=7140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}